136 related articles for article (PubMed ID: 24432794)
1. The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma.
Theodotou C; Shah AH; Hayes S; Bregy A; Johnson JN; Aziz-Sultan MA; Komotar RJ
Br J Neurosurg; 2014 Aug; 28(4):438-46. PubMed ID: 24432794
[TBL] [Abstract][Full Text] [Related]
2. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
[TBL] [Abstract][Full Text] [Related]
3. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review.
Ashby LS; Smith KA; Stea B
World J Surg Oncol; 2016 Aug; 14(1):225. PubMed ID: 27557526
[TBL] [Abstract][Full Text] [Related]
4. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
5. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.
Carlson JA; Reddy K; Gaspar LE; Ney D; Kavanagh BD; Damek D; Lillehei K; Chen C
J Neurooncol; 2015 Jun; 123(2):251-7. PubMed ID: 25920710
[TBL] [Abstract][Full Text] [Related]
7. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
Vymazal J; Wong ET
Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
[TBL] [Abstract][Full Text] [Related]
8. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
9. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
Vordermark D; Ruprecht K; Rieckmann P; Roggendorf W; Vince GH; Warmuth-Metz M; Kölbl O; Flentje M
BMC Cancer; 2006 Oct; 6():247. PubMed ID: 17049083
[TBL] [Abstract][Full Text] [Related]
12. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
13. The role of brachytherapy in the treatment of glioblastoma multiforme.
Barbarite E; Sick JT; Berchmans E; Bregy A; Shah AH; Elsayyad N; Komotar RJ
Neurosurg Rev; 2017 Apr; 40(2):195-211. PubMed ID: 27180560
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of intra-arterial versus intra-venous delivery of bevacizumab for the treatment of recurrent glioblastoma multiforme.
Burkhardt JK; Shin BJ; Schlaff CD; Riina H; Boockvar JA
J Exp Ther Oncol; 2011; 9(3):183-6. PubMed ID: 22070049
[TBL] [Abstract][Full Text] [Related]
15. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.
Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA
J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336
[TBL] [Abstract][Full Text] [Related]
16. Impact of tumor infiltrating CD63 positive cells on survival in patients with glioblastoma multiforme.
Kase M; Adamson A; Saretok M; Minajeva A; Vardja M; Jõgi T; Asser T; Jaal J
J Neurosurg Sci; 2016 Dec; 60(4):417-23. PubMed ID: 25215582
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).
Shibui S; Narita Y; Mizusawa J; Beppu T; Ogasawara K; Sawamura Y; Kobayashi H; Nishikawa R; Mishima K; Muragaki Y; Maruyama T; Kuratsu J; Nakamura H; Kochi M; Minamida Y; Yamaki T; Kumabe T; Tominaga T; Kayama T; Sakurada K; Nagane M; Kobayashi K; Nakamura H; Ito T; Yazaki T; Sasaki H; Tanaka K; Takahashi H; Asai A; Todo T; Wakabayashi T; Takahashi J; Takano S; Fujimaki T; Sumi M; Miyakita Y; Nakazato Y; Sato A; Fukuda H; Nomura K
Cancer Chemother Pharmacol; 2013 Feb; 71(2):511-21. PubMed ID: 23228988
[TBL] [Abstract][Full Text] [Related]
18. Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.
Kanner AA; Wong ET; Villano JL; Ram Z;
Semin Oncol; 2014 Oct; 41 Suppl 6():S25-34. PubMed ID: 25213871
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Zhang G; Huang S; Wang Z
J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]